| Cardiovascular Risk Management |
0 |
1 |
| Cardiac Surgery |
0 |
0.91 |
| Lipids Management |
0 |
0.75 |
| Coronary Artery Disease (CAD) |
0 |
0.69 |
| Heart |
0 |
0.63 |
| Heart Failure (HF) |
0 |
0.6 |
| Clinical Research |
0 |
0.49 |
| Valvular Heart Disease |
0 |
0.48 |
| Atrial Fibrillation |
0 |
0.42 |
| Healthcare and Medical Technology |
0 |
0.42 |
| Cardiovascular Imaging |
0 |
0.36 |
| Blood |
0 |
0.24 |
| SGLT2 Inhibitor |
0 |
0.24 |
| Statins |
0 |
0.24 |
| COVID-19 |
0 |
0.23 |
| Type 2 Diabetes Mellitus |
0 |
0.23 |
| COVID-19 Treatment |
0 |
0.19 |
| PCSK9 |
0 |
0.19 |
| GLP-1 Receptor Agonist |
0 |
0.18 |
| Cardiovascular disease |
0 |
0.15 |
| Diversity |
0 |
0.15 |
| Hospital |
0 |
0.15 |
| LDL Cholesterol |
0 |
0.15 |
| Meta-Analysis |
0 |
0.15 |
| Pandemic |
0 |
0.15 |
| Receptors |
0 |
0.15 |
| Social Determinants of Health |
0 |
0.15 |
| Cerebrovascular Accident |
0 |
0.14 |
| Renal Disease |
0 |
0.14 |
| Acute Coronary Syndrome |
0 |
0.12 |
| Chronic Kidney Disease |
0 |
0.12 |
| Electronic Health Record (EHR) |
0 |
0.12 |
| Renal Failure |
0 |
0.12 |
| Anticoagulation Therapy |
0 |
0.1 |
| Coronary Atherosclerosis |
0 |
0.1 |
| Ejection Fraction |
0 |
0.1 |
| Kidney |
0 |
0.1 |
| Obesity |
0 |
0.1 |
| Atherosclerosis |
0 |
0.08 |
| Percutaneous Coronary Intervention |
0 |
0.08 |
| Catheter Ablation |
0 |
0.07 |
| Familial Hypercholesterolemia |
0 |
0.07 |